George Blumenschein
Overview
Explore the profile of George Blumenschein including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1308
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Le X, Patel J, Shum E, Baik C, Sanborn R, Shu C, et al.
J Clin Oncol
. 2024 Oct;
43(4):403-411.
PMID: 39378386
Purpose: Preclinical studies demonstrated that dual inhibition of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) pathways delay the emergence of resistance to EGFR tyrosine kinase inhibitors...
2.
Zhang B, Lewis W, Stewart C, Morris B, Solis L, Serrano A, et al.
JTO Clin Res Rep
. 2024 Feb;
5(2):100623.
PMID: 38357092
Introduction: NSCLC transformation to SCLC has been best characterized with -mutant NSCLC, with emerging case reports seen in , , and -altered NSCLC. Previous reports revealed transformed SCLC from -mutant...
3.
Wang K, Du R, Roy-Chowdhuri S, Li Z, Hong L, Vokes N, et al.
JTO Clin Res Rep
. 2023 Aug;
4(8):100533.
PMID: 37649681
Introduction: amplification is a known resistance mechanism to tyrosine kinase inhibitor (TKI) treatment in -mutant NSCLC. Dual EGFR-MET inhibition has been reported with success in overcoming such resistance and inducing...
4.
Chang J, Lin S, Dong W, Liao Z, Gandhi S, Gay C, et al.
Lancet
. 2023 Jul;
402(10405):871-881.
PMID: 37478883
Background: Stereotactic ablative radiotherapy (SABR) is the standard treatment for medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or distant relapses, or both, are common. Immunotherapy reduces recurrence and...
5.
Nelson B, Tsimberidou A, Fu X, Fu S, Subbiah V, Sood A, et al.
Oncologist
. 2023 Jun;
28(12):1100-e1292.
PMID: 37311055
Background: Preclinical models suggest synergy between anti-angiogenesis therapy, mammalian target of rapamycin (mTOR), and histone deacetylase inhibitors to promote anticancer activity. Methods: This phase I study enrolled 47 patients between...
6.
Ferrarotto R, Sousa L, Feng L, Mott F, Blumenschein G, Altan M, et al.
J Clin Oncol
. 2023 Mar;
41(15):2843-2851.
PMID: 36898078
Purpose: We conducted a phase II trial evaluating the efficacy of VEGFR inhibitor axitinib and PD-L1 inhibitor avelumab in patients with recurrent/metastatic adenoid cystic carcinoma (R/M ACC). Patients And Methods:...
7.
Liu Y, Yao L, Kalhor N, Carter B, Altan M, Blumenschein G, et al.
Lung Cancer
. 2022 Nov;
174:112-117.
PMID: 36371941
Introduction: The phase II DETERRED trial assessed the safety and efficacy of consolidation and concurrent immunotherapy with chemoradiation in unresectable locally advanced non-small cell lung cancer. We present updated efficacy...
8.
Gillison M, Blumenschein G, Fayette J, Guigay J, Colevas A, Licitra L, et al.
Oncologist
. 2022 May;
27(2):e194-e198.
PMID: 35641218
In the randomized, phase 3 CheckMate 141 trial, nivolumab significantly improved overall survival (OS) versus investigator's choice (IC) of chemotherapy at primary analysis among 361 patients with recurrent or metastatic...
9.
Nagasaka M, Molife C, Cui Z, Stefaniak V, Li X, Kim S, et al.
Future Oncol
. 2022 Mar;
18(16):1963-1977.
PMID: 35354280
This retrospective study estimated efficacy and safety of sintilimab + pemetrexed + platinum (SPP) versus placebo + pemetrexed + platinum (PPP) in untreated locally advanced/metastatic, nonsquamous non-small-cell lung cancer (NSCLC),...
10.
Ferrarotto R, Sousa L, Qing Y, Kaya D, Stephen B, Jain D, et al.
Adv Ther
. 2021 Jul;
38(8):4581-4591.
PMID: 34241781
Introduction: Patients with advanced cutaneous squamous cell carcinoma (CSCC) have a poor prognosis. Blocking the PD-1-PD-L1 axis has shown promising activity in this patient population. We assessed the safety and...